In patients with ASCVD and elevated LDL-C with maximal statin therapy, inclisiran reduced LDL-C levels at 18 months.
Where this comes from
- Record sourced from PubMed, PMID 32805173.
- Also identified by DOI 10.7326/ACPJ202008180-018.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ray KK, Wright RS, Kallend D, et al. <b>Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.</b> N Engl J Med. 2020;382:1507-19. 32187462.
Medical subject headings
- Hydroxymethylglutaryl-CoA Reductase Inhibitors